Literature DB >> 2877314

Adjuvant chemotherapy combined with tamoxifen in postmenopausal patients with stage II breast cancer.

C C Zielinski, E Kubista, H Salzer, P Sevelda, M Langer, A Staffen, J Spona, P Aiginger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2877314     DOI： 10.1016/s0140-6736(86)90577-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer.

Authors:  E Tichatschek; C C Zielinski; C Müller; P Sevelda; E Kubista; K Czerwenka; J Spona; H Wolf; M M Eibl
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre.

Authors:  L Mauriac; M Durand; J Chauvergne; F Bonichon; A Avril; P Mage; M H Dilhuydy; A Le Treut; J Wafflart; D Marée
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

3.  Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer.

Authors:  C C Zielinski; I Stuller; P Rausch; C Müller
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.